Solid Tumors
Conditions
Brief summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.
Interventions
DRUG9MW2821
All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Sponsors
Mabwell (Shanghai) Bioscience Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form. 2. Male or female subjects aged 18 to 80 years (including 18 and 80 years). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histologically or cytologically confirmed advanced malignant solid tumors (except sarcoma). 5. For Cohort Expansion: Subjects must submit tumor tissue for Nectin-4 expression. 6. Life expectancy of ≥ 3 months. 7. Subjects must have measurable disease according to RECIST (version 1.1). 8. Adequate organ functions. 9. Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy. 10. Subjects are willing to follow study procedures.
Exclusion criteria
1. Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug, or any other anticancer therapy within 14 days prior to the first dose of study drug. 2. Preexisting treatment related toxicity Grade ≥ 2 (except alopecia). 3. Major surgery within 28 days prior to first dose of study drug. 4. History of uncontrolled diabetes mellitus. 5. Preexisting peripheral neuropathy Grade ≥ 2. 6. Received treatment of nectin-4 targeted ADC with MMAE payload. 7. Any live vaccines within 4 weeks before first dose of study drug or during the study. 8. Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug. 9. Other severe or uncontrolled disease, i.e. severe respiratory system disease, thromboembolic events, active bleeding or active infection. 10. Uncontrolled central nervous system metastases. 11. History of another malignancy within 3 years before the first dose of study drug. Subjects with curable malignancies are allowed. 12. History of autoimmune disease requiring systemic treatment within 2 years before the first dose of study drug. 13. Has ocular conditions that may increase the risk of corneal epithelium damage. 14. Known sensitivity to any of the ingredients of the investigational product; History of drug abuse or mental illness. 15. Any P-glycoprotein (P-gp) inducers/inhibitors or CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug 16. Use of any investigational drug or device within 2 months prior to the first dose of study drug. 17. Condition or situation which may put the subject at significant risk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | Up to 28 days post last drug administration | — |
| Objective Response Rate (Phase 2) | Up to 24 months | Defined as the percentage of subjects who experience a best response of either CR or PR. CR and PR must be confirmed ≥ 28 days later. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | Up to 24 months | Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause. DOR is only defined for subjects who have best overall response of CR or PR. |
| Time to Response | Up to 24 months | Time from the date of first infusion to the date of confirmed CR or PR |
| Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE) | 24 months | Maximum observed concentration (Cmax) |
| Overall Survival | Up to 24 months | Time from the date of first infusion until the date of death from any cause. |
| Incidence of Anti-Drug Antibody (ADA) | Up to 24 months | — |
| Progression Free Survival | Up to 24 months | Time from the date of first infusion to the earliest date of documented disease progression per radiological evidence or death from any cause |
| Disease Control Rate | Up to 24 months | Defined as the percentage of subjects who experience a best response of CR, PR or stable disease (SD) |
Countries
China
Outcome results
None listed